Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro

British Journal of Cancer

Volumn 89, Issue 11, 2003, Pages 2133-2139

  Koch, S ^a   Mayer, F ^a   Honecker, F ^a   Schittenhelm, M ^a   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cytotoxic drugs; Hypoxia; In vitro; Normoxia; Testicular germ cell tumours (TGCTs)

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; BLEOMYCIN; CARBOPLATIN; CDDP; CISPLATIN; CYTOTOXIC AGENT; ERYTHROPOIETIN; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; HEMOGLOBIN; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; EMBRYONAL CARCINOMA; FLOW CYTOMETRY; GERM CELL TUMOR; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; IC 50; IN VITRO STUDY; METASTASIS; OUTCOMES RESEARCH; OXYGENATION; PRIORITY JOURNAL;

EID: 0347419309     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601375     Document Type: Article

References (49)

1. Becker A, Stadler P, Lavey RS, Haensgen G, Kuhnt T, Lautenschlaeger C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46: 459-466
2. Bokemeyer C, Beyer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34
3. Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J, Kanz L (2002) Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87: 1066-1071
4. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416
5. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73: 592-599
6. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21: 366-373
7. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394
8. Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, Chester KA (2001) A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res 61: 3653-3659
9. Einhorn LH (2002) Chemotherapeutic and surgical strategies for germ cell tumors. Chest Surg Clin N Am 12: 695-706
10. Goldstein LJ (1996) MDR1 gene expression in solid tumours. Eur J Cancer 6: 1039-1050
11. Hoeckel M, Schlenger K, Aral B, Mitze M, Schaeffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515
12. Hoeckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276
13. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136
14. Iyer VN, Szybalski W (1964) Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 145: 55
15. Kennedy KA, Rockwell S, Sartorelli AC (1980) Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40: 2356-2360
16. Kennedy KA, Siegfried JM, Sartorelli AC, Tritton TR (1983) Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 43: 54-59
17. Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo JA, Peehl DM, Giaccia AJ (1997) Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 57: 4200-4204
18. Kinoshita M, Johnson DL, Shatney CH, Lee YL, Mochizuki H (2001) Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int J Cancer 91: 322-326
19. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20: 2031-2037
20. Kondo J, Arii S, Furutani M, Isigami SI, Mori A, Onodera H, Chiba T, Imamura M (2000) Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 88: 1820-1827
21. Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB (2001) Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 61: 7603-7607
22. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL (2001) Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832
23. Kovacs MS, Hocking DJ, Evans JW, Sum BG, Wouters BG, Brown JM (1999) Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80: 1245-1251
24. Lautier D, Canitrot Y, Deeley RG, Cole SP (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977
25. Liang BC (1996) Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29: 149-155
26. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB (2001) p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61: 1508-1516
27. Lin X, Ramamurthi K, Mishima M, Kondo A, Howell SB (2000) p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol Pharmacol 58: 1222-1229
28. López-Barneo J, Pardal R, Ortega-Sáenz P (2001) Cellular mechanisms of oxygen sensing. Annu Rev Physiol 63: 259-287
29. Luk CK, Veinot-Debrot L, Tjan E, Tannock IF (1990) Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 82: 684-692
30. Mayer F, Honecker F, Looijenga LHJ, Bokemeyer C (2003) Towards understanding of the biological basis of chemotherapy response in germ cell tumors. Ann Oncol 14: 825-832
31. Mottram JC (1931) A factor of importance in the radio-sensitivity of tumours. Br J Radiol 9: 606-614
32. Motzer RJ, Chou TC, Schwartz L, Bosl GJ, Bajorin DF, Hutter H (1995) Paclitaxel in germ cell cancer. Semin Oncol 22: 12-15
33. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418
34. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279
35. Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced aquamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39
36. Rockwell S (1986) Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 38: 229-235
37. Sanna K, Rofstad EK 1994 Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58: 258-262
38. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103
39. Shelley MD, Burgon K, Mason MD (2002) Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat Rev 28: 237-253
40. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA (1995) The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 33: 813-823
41. Sikic BI (1986) Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv 5: 81-91
42. Skov KA, Adomat H, Farrell NP, Matthews JB (1998) Assessment of toxicity of bis-platinum complexes in hypoxic and aerobic cells. Anticancer Drug Des 13: 207-220
43. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC (1981) Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 41: 1096-1099
44. Vaupel P, Hoeckel M (1998) Oxygenation of human tumors. In Blood Perfusion and Microenvironment of Human Tumors Molls M, Vaupel P (eds) Berlin, Germany: Springer
45. Vaupel P, Kelleher DK, Hoeckel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28: 29-35
46. Wang N, Perkins KL, Bronson DL, Fraley EE (1981) Cytogenetic evidence for premeiotic transformation of human testicular cancers. Cancer Res 41: 2135-2140
47. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor-1 and reactive oxygen species. FASEB J 17: 503-505
48. Yamagata M, Kanematsu T, Matsumata T, Utsunomiya T, Ikada Y, Sugimachi K (1992) The difference in chemosensitivity to antineoplastic agents of human hepatocellular carcinoma cells under normo-oxygenated or hypoxic conditions. Eur J Surg Oncol 18: 379-382
49. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835